Nicaraven: Chugai

Current Opinion in Investigational Drugs

Volumn 4, Issue 1, 2003, Pages 83-90

  Leker, Ronen R ^a  

^a Laboratory of Biochemistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTEVAN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOPTOSIS INHIBITOR; DEXANABINOL; DIZOCILPINE; GAVESTINEL; NICARAVEN; PLACEBO; TIRILAZAD; TISSUE PLASMINOGEN ACTIVATOR;

ANTIOXIDANT ACTIVITY; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN VASOSPASM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; HEADACHE; HUMAN; LIVER TOXICITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PROTECTION; REGISTRATION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SUBARACHNOID HEMORRHAGE; TOXICITY TESTING;

ANIMALS; ANTIOXIDANTS; BRAIN EDEMA; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; NEUROPROTECTIVE AGENTS; NIACINAMIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037281605     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. 78792 Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemic in the cat. Ozyurt E, Graham DI, Woodruff GN, McCulloch J J Cereb Blood Flow Metab 1988 8 1 138-143
2. 83087 The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J J Ann Neurol 1988 24 4 543-551
3. 171224 Chugai's plans for nicaraven in Japan. 1995 1992 26
4. 176094 Clinical experience with excitatory amino acid antagonist drugs. Muir KW, Lees KR Stroke 1995 26 3 503-513 Compares clinical experience for different NMDA antagonists. Excellent discussion of central nervous system and cardiovascular effects of different agents written by leading investigators who have been involved in the trials of most of the agents discussed.
5. 179885 The beneficial effect of hydroxyl radical scavenger, AVS, on symptomatic vasospasm following subarachnoid hemorrhage: Results of a multi-centre, double-blind placebo-controlled trial. Asano T, Sano K, Takakura K, Kikuchi H, Nagai H, Saito I, Tamura A, Ochiai C, Sasaki T J Cereb Blood Flow Metab 1995 15 Suppl 1 S161 2051-2052
6. 205152 Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy. Grotta J J Intern Med 1995 237 1 89-94
7. 230780 Neuroprotection after several days of mild, drug-induced hypothermia. Nurse S, Corbett D J Cereb Blood Flow Metab 1996 16 3 474-480
8. 238255 Attenuation of ischemia-reperfusion injury in the rat neocortex by the hydroxyl radical scavenger nicaraven. Toyoda T, Kassell NF, Lee KS, Zlokovi BV, Selman WR, Megyesi JF, Findlay JM Neurosurgery 1997 40 2 372-378
9. 238256 The role of a hydroxyl radical scavenger (nicaraven) in recovery of cardiac function following preservation and reperfusion. Ku K, Kin S, Hashimoto M, Saitoh Y, Nosaka S, Iwasaki S, Alam MS, Nakayama K Transplantation 1996 62 8 1090-1095
10. 238257 Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: Results of a multicenter, placebo-controlled double-blind trial. Asano T, Takakura K, Sano K, Kikuchi H, Nagai H, Saito I, Tamura A, Ochiai C, Sasaki T J Neurosurg 1996 84 5 792-803
11. 238258 Sequential observations of brain edema with proton magnetic resonance imaging and spectroscopy. Kamada K Hokkaido Igaku Zasshi 1996 71 1 105-122
12. 238261 Reaction of microglial cells and macrophages after cortical incision in rats: Effect of a synthesized free radical scavenger, (±)-N,N′-propylenedinicotinamide (AVS). Masana Y, Yoshimine T, Fujita T, Maruno M, Kumura E, Hayakawa T Neurosci Res 1995 23 2 217-221
13. 238262 Mutagenicity study on AVS. Inoue M, Horiuchi K, Fukuda T, Fukuda A, Marutani K Jpn Pharmacol Ther 1995 23 Suppl 1 207-212
14. 238263 Antigenicity study on AVS. Inoue M, Satoh T, Niki R Jpn Pharmacol Ther 1995 23 Suppl 1 203-206
15. 238264 A perinatal and postnatal study of AVS in rats. Igarashi S, Imai S, Tauchi K, Takeshima T, Sudo M, Sudo T Jpn Pharmacol Ther 1995 23 Suppl 1 191-202
16. 238265 A teratological study of AVS in rabbits. Hara H, Nakagawa T, Kasuga Y, Marutani K, Deki T, Ohtani T Jpn Pharmacol Ther 1995 23 Suppl 1 185-190
17. 238266 A fertility study of AVS in rats. Hara H, Imai S, Tauchi K, Toyohara S, Morita N, Huan K J, Sudo M, Tsuemoto Y, Takeshima T, Koyama Y, Sudo T Jpn Pharmacol Ther 1995 23 Suppl 1 155-164
18. 238267 Six-month intravenous toxicity study of AVS in dogs. Otabe K, Tamura H, Ohtaki K, Tsunemi K, Haruta K, Homma N, Ohtani T Jpn Pharmacol Ther 1995 23 Suppl 1 103-153
19. 238268 Six-month intraperitoneal toxicity study of AVS in rats with two-month post-treatment recovery period. Itoh T, Deki T, Uchiyama T, Nakagawa T, Higo S, Sakamaki Y, Marutani K, Tsurukawa K, Yahashi H, Ohtani T Jpn Pharmacol Ther 1995 23 Suppl 1 69-102
20. 238269 One month intravenous toxicity study of AVS in dogs. Otabe K, Tamura H, Ohtaki K, Tsunemi K, Haruta K, Homma N, Ohtani T Jpn Pharmacol Ther 1995 23 Suppl 1 41-68
21. 238270 One month intraperitoneal toxicity study of AVS in rats. Itoh T, Furono T, Sugimoto T, Yamada S, Komatsu H, Noguchi G. Jpn Pharmacol Ther 1995 23 Suppl 1 21-39
22. 238271 Single-dose intravenous toxicity study of AVS in dogs. Noguchi N, Ohtaki K, Tamura H, Tsunemi K, Haruta K, Homma N, Ohtani T Jpn Pharmacol Ther 1995 23 Suppl 1 13-19
23. 238273 A high-field magnetic resonance imaging study of experimental vasogenic brain edema and its response to AVS: 1,2-Bis(nicotinamido)-propane. Kamada K, Houkin K, Iwasaki Y, Abe H Acta Neurochir Suppl Wien 1994 60 491-493
24. 238274 Experimental studies on nicaraven as radioprotector - Free radical scavenging effect and the inhibition of the cellular injury. Mori Y, Takashima H, Seo H, Yamamoto G, Liu J, Ohkawa M, Tanabe M Nippon Igaku Hoshasen Gakkai Zasshi 1993 53 6 704-712
25. 250617 Hydroxyl radical scavenging effect of nicaraven in myocardial and coronary endothelial preservation and reperfusion injury. Alam MS, Ku K, Hashimoto M, Nosaka S, Saitoh Y, Yamauchi M, Masumura S, Nakayama K, Tamura K Cardiovasc Res 1997 33 3 686-692
26. 250618 Single-dose intravenous toxicity study of AVS in rats. Noguchi N, Noguchi G, Hirano T, Niki R Jpn Pharmacol Ther 1995 23 Suppl 1 9-12
27. 250619 Single-dose intravenous toxicity study of AVS in mice. Noguchi N, Matsuoka A, Yokota K, Shiota S, Niki R Jpn Pharmacol Ther 1995 23 Suppl 1 5-8
28. 250623 Amelioration of ischaemic cerebral oedema by a free radical scavenger, AVS: 1,2-Bis(nicotinamido)-propane. An experimental study using a regional ischaemia model in cats. Asano T, Johshita H, Koide T, Takakura K Neurol Res 1984 6 4 163-168
29. 240697 Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Shohami E, Novikov M, Bass R Brain Res 1995 674 1 55-62
30. 240901 Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Bowes MP, Rothlein R, Fagan SC, Zivin JA Neurology 1995 45 4 815-819
31. 306248 Drug development pipeline: Maxacalcitol, hyaluronic acid, Chugai, nicaraven, epoetin beta, Gentics Inst/Chugai, nicorandil, raloxifene, letrozole, sevelamer hydrochloride, ED-71, MRA, GM-611, MX-68, lenograstim, octafluropropane. Chugai Pharmaceuticals Co Ltd Company Communication 1998 November 15
32. 306710 Metabolism of 2(R,S)-1,2-bis(nicotinamido) propane, a new agent with anti-vasospasm activity, in rats and rabbits. Ishigai M, Ishitani Y, Orikasa Y, Kamiyama H, Kumaki K Arzneimittelforschung 1998 48 5 429-435
33. 306712 Protective effects of nicaraven, a new hydroxyl radical scavenger, on the endothelial dysfunction after exposure of pig coronary artery to hydroxyl radicals. Alam MS, Ku K, Yamauchi M, Hashimoto M, Nosaka S, Hossain MS, Masumura S, Nakayama K, Tamura K Mol Cell Biochem 1998 178 1-2 237-243
34. 309983 Antivasospastic and brain-protective effects of a hydroxyl radical scavenger (AVS) after experimental subarachnoid hemorrhage. Germano A, Imperatore C, D'Avella D, Costa G, Tomasello F J Neurosurg 1998 88 6 1075-1081
35. 339358 Neoral, Diovan to be blockbuster: Novartis. Pharma Jpn 1999 1662 14-15
36. 342898 Clinical trial update: Neuroprotection against acute ischaemic stroke. Devuyst G, Bogousslavsky J Curr Opin Neurol 1999 12 1 73-79
37. 355854 Ischemia-induced neuronal apoptosis. Choi DW Curr Opin Neurobiol 1996 6 5 667-672
38. 372198 Quantitative analysis of the kinetic constant of the reaction of N,N′-propylenedinicotinamide with the hydroxyl radical using dimethyl sulfoxide and deduction of its structure in chloroform. Akimoto T Chem Pharm Bull (Tokyo) 2000 48 4 467-476
39. 372523 Caspases as treatment targets in stroke and neurodegenerative diseases. Schulz JB, Weller M, Moskowitz MA Ann Neurol 1999 45 4 421-429
40. 375869 Dexanabinol; A novel neuroprotective drug in experimental focal cerebral ischemia. Leker RR, Shohami E, Abramsky O, Ovadia H J Neurol Sci 1999 162 2 114-119
41. 409025 Chugai starts V's 21 Plan: President Nagayama. Pharm Jpn 2001 1745 1
42. 416331 Neuroprotective agents in traumatic brain injury. Maas AIR Expert Opin Investig Drugs 2001 10 4 753-767
43. 422477 New drugs in the R&D pipeline: Chugai. Pharma Jpn 2001 1762 27-28
44. 424491 Neuroprotection for acute stroke: Making clinical trials work. Muir KW, Grosset DG 1999 30 1 180-182
45. 425301 Inflammatory mediators and stroke: New opportunities for novel therapeutics. Barone FC, Feuerstein GZ J Cereb Blood Flow Metab 1999 19 8 819-834
46. 425320 The role of inflammation after acute stroke: Utility of pursuing anti-adhesion molecule therapy. DeGraba TJ Neurology 1998 51 3 SUPPL 3 62-68
47. 448015 Investor Presentation - April 2002. Roche Holding AG Company Presentation 2002 April 16
48. 460177 New drugs in the R&D pipeline. Pharma Jpn 2002 1806 1-20
49. 466457 Chugai: Development Pipeline. Chugai Pharmaceutical Co Ltd Company World Wide Web Site 2002 October 11
50. 466916 New drugs in the R&D pipeline. Pharma Jpn 2002 1815 October 14
51. 473336 Cerebral ischemia and trauma - Different etiologies yet similar mechanisms: Neuroprotective opportunities. Leker RR, Shohami E Brain Res Brain Res Rev 2002 39 1 55-73
52. 473515 Pathobiology of ischaemic stroke: An integrated view. Dimagl U, Iadecola C, Moskowitz MA Trends Neurosci 1999 22 9 391-397
53. 473553 Reactive oxygen radicals in signaling and damage in the ischemic brain. Chan PH J Cereb Blood Flow Metab 2001 21 1 2-14
54. 473630 Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Feuerstein GZ, Wang X, Barone FC Ann NY Acad Sci 1997 825 15 179-193
55. 473632 The role of inflammation and cytokines in brain injury. Arvin B, Neville LF, Barone FC, Feuerstein GZ Neurosci Biobehav Rev 1996 20 3 445-452
56. 473634 Antagonizing excitotoxicity: A therapeutic strategy for stroke? Choi D Mt Sinai J Med 1998 65 2 133-138
57. 473676 Nitric oxide synthase in models of focal ischemia. Samdani AF, Dawson TM, Dawson VL Stroke 1997 28 6 1283-1288
58. 473684 Review of oxidative stress in brain and spinal cord injury: Suggestions for pharmacological and nutritional management strategies. Juurlink BH, Paterson PG J Spinal Cord Med 1998 21 4 309-334
59. 473701 Free radicals in brain metabolism and pathology. Evans PH Br Med Bull 1993 49 3 577-587
60. 473767 Oxidative processes and antioxidative defense mechanisms in the aging brain. Reiter RJ FASEB J 1995 9 7 526-533
61. 473771 Nitroxide SOD-mimics: Modes of action. Samuni A, Mitchell JB, DeGraff W, Krishna CM, Samuni U, Russo A Free Radic Res Commun 1991 12-13 1 187-194
62. 473774 Nitroxides as antioxidants. Krishna MC, Samuni A Methods Enzymol 1994 234 580-589
63. 473777 Neuroprotective interaction effects of NMDA and AMPA receptor antagonists in an in vitro model of cerebral ischemia. Arias RL, Tasse JR, Bowlby MR Brain Res 1999 816 2 299-308
64. 473780 Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Schulz JB, Weller M, Matthews RT, Heneka MT, Groscurth P, Martinou JC, Lommatzsch J, Von Coelln R, Wullner U, Loschmann PA, Beal MF et al Cell Death Differ 1998 5 10 847-857
65. 473784 Advances in neuroprotection trials. Lees KR Eur Neurol 2001 45 1 6-10
66. 473785 Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial. GAIN International Investigators. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J Lancet 2000 355 9219 1949-1954
67. 473787 Cerestat and other NMDA antagonists in ischemic stroke. Lees KR Neurology 1997 49 5 Suppl 4 66-69
68. 473790 Effect of tirilazad on brain nitric oxide synthase activity during cerebral ischemia in rats. Del Pilar FRM, Belmonte A, Meizoso MJ, Garcia NM, Garcia IE Pharmacology 1997 54 2 108-112
69. 473792 The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. Taylor BM, Fleming WE, Benjamin CW, Wu Y, Mathews WR, Sun FF J Pharmacol Exp Ther 1996 276 3 1224-1231
70. 473802 Deficiency of intercellular adhesion molecule 1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia. Kitagawa K, Matsumoto M, Mabuchi T, Yagita Y, Ohtsuki T, Hori M, Yanagihara T J Cereb Blood Flow Metab 1998 18 12 1336-1345
71. 473968 Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. Chopp M, Li Y, Jiang N, Zhang RL, Prostak J J Cereb Blood Flow Metab 1996 16 4 578-584
72. 473969 Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. Cheng Y, Deshmukh M, D'Costa A, Demaro JA, Gidday JM, Shah A, Sun Y, Jacquin MF, Johnson EM, Holtzman DM J Clin Invest 1998 101 9 1992-1999
73. 473980 Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo. Wiessner C, Sauer D, Alaimo D, Allegrini PR Cell Mol Biol 2000 46 1 53-62
74. 473981 Rodent models of stroke limitations. What can we learn from recent clinical trials of thrombolysis? Grotta J Arch Neurol 1996 53 10 1067-1070
75. 473982 Clinical trials in acute stroke: Why have they not been successful? Del Zoppo GJ Neurology 1998 51 3 Suppl 3 59-61
76. 473983 Neuroprotective therapies in stroke. Zivin JA Drugs 1997 54 3 88-89
77. 473987 Factors determining the therapeutic window for stroke. Zivin JA Neurology 1998 50 3 599-603
78. 473995 Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Lavie G, Teichner A, Shohami E, Ovadia H, Leker RR Brain Res 2001 901 1-2 195-201
79. 474003 Brain cooling during transient focal ischemia provides complete neuroprotection. Barone FC, Feuerstein GZ, White RF Neurosci Biobehav Rev 1997 21 1 31-44
80. 474010 Mild hypothermia improves recovery of cortical extracellular potassium ion activity and excitability after middle cerebral artery occlusion in the rat. Sick TJ, Xu G, Perez Pinzon MA Stroke 1999 30 11 2416-2421
81. 474012 Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: Effects on neurologic outcome, infarct size, apoptosis, and inflammation. Maier CM, Ahern K, Cheng ML, Lee JE, Yenari MA, Steinberg GK Stroke 1998 29 10 2171-2180
82. 474015 Therapeutic effect of tirilazad mesylate (U-74006F), mannitol, and their combination on experimental ischemia. Oktem IS, Menku A, Akdemir H, Kontas O, Kurtsoy A, Koc RK Res Exp Med 2000 199 4 231-242
83. 474016 Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Schabitz WR, Li F, Irie K, Sandage BW, Locke KW, Fisher M Stroke 1999 30 2 427-431
84. 474017 Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: Combination studies with the thrombolytic tissue plasminogen activator. Lapchak PA, Chapman DF, Zivin JA Stroke 2001 32 1 147-153
85. 474267 Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: A randomized controlled trial. Sacco RL, DeRosa JT, Haley EC, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL J Am Med Assoc 2001 285 13 1719-1728
86. 474379 Improvement in cerebral blood flow and metabolism following subarachnoid hemorrhage in response to prophylactic administration of the hydroxyl radical scavenger, AVS, (±)-N,N′-propylenedinicotinamide: A positron emission tomography study in rats. Yamamoto S, Tenq W, Nishizawa S, Kakiuchi T, Tsukada H J Neurosurg 2000 92 6 1009-1015
87. 474393 Changes in guanylate cyclase activity in arteriolar smooth muscle cells and hemodynamics after ischemia-reperfusion in rats. Hashimoto H, Ohta S, Utsonomiya H, Kumon Y, Sakaki S, Matsuda S, Sakanaka M Acta Neuropathol 1998 603 6 603-613
88. 474431 A novel hydroxyl radical scavenger, nicaraven, protects the liver from warm ischemia and reperfusion injury. Yokata R, Fukai M, Shimamura T, Suzuki T, Watanabe Y, Nagashima K, Kishida A, Furukawa H, Hayashi T, Todo S Surgery 2000 127 6 661-669
89. 474432 Effects of nicaraven on nitric oxide-related pathways and in shock and inflammation. Zingarelli B, Scott GS, Hake P, Salzman AL, Szabo C Shock 2000 13 2 126-134
90. 474434 Effects of the radical scavenger AVS on behavioral and BBB changes after experimental subarachnoid hemorrhage. Imperatore C, Germano A, D'Avella D, Tomasello F, Costa G Life Sci 2000 66 9 779-790
91. 474622 Experimental evaluation of the beneficial effect of an antioxidant on cerebral vasospasm. Asano T, Sasaki T, Koide T, Takakura K, Sano K Neurol Res 1984 6 1-2 49-53
92. 475238 Healthcare - Focus on value and defensiveness. Mita M, Muraoka S Morgan Stanley Dean Witter 2002 September 12 103
93. 475769 Neuroprotective therapy for the treatment of acute ischemic stroke. Naritomi H Rinsho Shinkeigaku 2001 41 12 1060-1063
94. 475775 Protective effect of nicaraven against prolonged cold kidney preservation and reperfusion injury. Transplant Proc 1998 30 7 3758-3760